ANIXA BIOSCIENCES INC EBITDA 2010-2022 | ANIX

ANIXA BIOSCIENCES INC ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
ANIXA BIOSCIENCES INC Annual EBITDA
(Millions of US $)
2021 $-13
2020 $-10
2019 $-11
2018 $-14
2017 $-6
2016 $-4
2015 $-0
2014 $-4
2013 $-7
2012 $-4
2011 $-5
2010 $-5
2009 $-7
ANIXA BIOSCIENCES INC Quarterly EBITDA
(Millions of US $)
2022-01-31 $-4
2021-10-31 $-4
2021-07-31 $-4
2021-04-30 $-2
2021-01-31 $-2
2020-10-31 $-2
2020-07-31 $-2
2020-04-30 $-3
2020-01-31 $-3
2019-10-31 $-2
2019-07-31 $-2
2019-04-30 $-2
2019-01-31 $-5
2018-10-31 $-5
2018-07-31 $-6
2018-04-30 $-1
2018-01-31 $-2
2017-10-31 $-2
2017-07-31 $-2
2017-04-30 $-1
2017-01-31 $-1
2016-10-31 $-1
2016-07-31 $-1
2016-04-30 $-1
2016-01-31 $-1
2015-10-31 $-1
2015-07-31 $-1
2015-04-30 $-2
2015-01-31 $4
2014-10-31 $-1
2014-07-31 $0
2014-04-30 $-1
2014-01-31 $-2
2013-10-31 $-2
2013-07-31 $-2
2013-04-30 $-1
2013-01-31 $-2
2012-10-31 $-2
2012-07-31 $-1
2012-04-30 $-1
2012-01-31 $-1
2011-10-31 $-1
2011-07-31 $-1
2011-04-30 $-1
2011-01-31 $-2
2010-10-31 $-1
2010-07-31 $-1
2010-04-30 $-1
2010-01-31 $-2
2009-10-31 $-3
2009-07-31 $-1
2009-04-30 $-1
2009-01-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.099B $0.001B
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00